GB9111902D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB9111902D0
GB9111902D0 GB919111902A GB9111902A GB9111902D0 GB 9111902 D0 GB9111902 D0 GB 9111902D0 GB 919111902 A GB919111902 A GB 919111902A GB 9111902 A GB9111902 A GB 9111902A GB 9111902 D0 GB9111902 D0 GB 9111902D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB919111902A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9111902(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB919111902A priority Critical patent/GB9111902D0/en
Publication of GB9111902D0 publication Critical patent/GB9111902D0/en
Priority to UA93004068A priority patent/UA41265C2/uk
Priority to IL10207392A priority patent/IL102073A/en
Priority to MX9202619A priority patent/MX9202619A/es
Priority to RU93058495A priority patent/RU2102393C1/ru
Priority to IS3873A priority patent/IS1867B/is
Priority to TW081104300A priority patent/TW254939B/zh
Priority to PCT/EP1992/001213 priority patent/WO1992021676A1/en
Priority to AU18810/92A priority patent/AU1881092A/en
Priority to EP01200491A priority patent/EP1099700A1/en
Priority to AT92109221T priority patent/ATE212630T1/de
Priority to AU17361/92A priority patent/AU656379B2/en
Priority to CA002070230A priority patent/CA2070230C/en
Priority to DK92109221T priority patent/DK0517145T3/da
Priority to US07/892,029 priority patent/US5905082A/en
Priority to PT92109221T priority patent/PT517145E/pt
Priority to KR1019920009537A priority patent/KR100244008B1/ko
Priority to APAP/P/1992/000395A priority patent/AP300A/en
Priority to GEAP19922654A priority patent/GEP19991834B/en
Priority to DE69232387T priority patent/DE69232387T2/de
Priority to NO922182A priority patent/NO301713B1/no
Priority to CA002311988A priority patent/CA2311988C/en
Priority to SK1257-93A priority patent/SK281249B6/sk
Priority to ES92109221T priority patent/ES2171158T3/es
Priority to EP92109221A priority patent/EP0517145B1/en
Priority to ZA924007A priority patent/ZA924007B/xx
Priority to CS932612A priority patent/CZ284513B6/cs
Priority to JP4166809A priority patent/JP2851480B2/ja
Priority to SG1996004763A priority patent/SG52455A1/en
Priority to NZ242981A priority patent/NZ242981A/en
Priority to IE20020782A priority patent/IE20020782A1/en
Priority to IE178092A priority patent/IE921780A1/en
Priority to IS4268A priority patent/IS4268A/is
Priority to OA60437A priority patent/OA09913A/en
Priority to BG98254A priority patent/BG60914B1/bg
Priority to HK98110312.3A priority patent/HK1009599B/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Medicinal Preparation (AREA)
GB919111902A 1991-06-03 1991-06-03 Chemical compounds Pending GB9111902D0 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds
UA93004068A UA41265C2 (uk) 1991-06-03 1992-02-06 Кристалічна форма (-)-цис-4-аміно-1-(2-гідроксиметил-1,3-оксатіолан-5-іл)-(1н)-піримідин-2-ону (варіанти), способи її отримання та фармацевтична композиція
SG1996004763A SG52455A1 (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
NZ242981A NZ242981A (en) 1991-06-03 1992-06-02 The compound (-)cis-4-amino-1-(2-hydroxymethyl- 1,3-oxathiolan-5-yl)-(1h)-pyrimidin-2-one in crystalline form and pharmaceutical compositions thereof
APAP/P/1992/000395A AP300A (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives.
DE69232387T DE69232387T2 (de) 1991-06-03 1992-06-02 Kristallinische Oxathiolanderivate
RU93058495A RU2102393C1 (ru) 1991-06-03 1992-06-02 (-)-цис-4-амино-1-(2-оксиметил-1,3-оксатиолан-5-ил-(1н)-пиримидин-2-он в кристаллических формах, способы их получения и фармацевтическая композиция
IS3873A IS1867B (is) 1991-06-03 1992-06-02 Hliðstæð aðferð til framleiðslu á kristölluðum oxaþíólan afleiðum
TW081104300A TW254939B (enExample) 1991-06-03 1992-06-02
PCT/EP1992/001213 WO1992021676A1 (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
AU18810/92A AU1881092A (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
EP01200491A EP1099700A1 (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
AT92109221T ATE212630T1 (de) 1991-06-03 1992-06-02 Kristallinische oxathiolanderivate
AU17361/92A AU656379B2 (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
CA002070230A CA2070230C (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
DK92109221T DK0517145T3 (da) 1991-06-03 1992-06-02 Krystallinske oxathiolanderivater
US07/892,029 US5905082A (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
PT92109221T PT517145E (pt) 1991-06-03 1992-06-02 Derivados cristalinos do oxatiolano
KR1019920009537A KR100244008B1 (ko) 1991-06-03 1992-06-02 결정질 옥사티올란 유도체
IL10207392A IL102073A (en) 1991-06-03 1992-06-02 S (Zis - 4 - Amino - 1 -) 2 - Hydroxymethyl - 1, Oxathiolan - - 5 - Il (-) H1 (- Pyrimidine - 2 - and crystalline preparation and pharmaceutical preparations containing or
GEAP19922654A GEP19991834B (en) 1991-06-03 1992-06-02 Crystalline Oxathiolane Derivatives
MX9202619A MX9202619A (es) 1991-06-03 1992-06-02 Derivados de oxa tiolano cristalino, metodo para su preparacion y formulacion farmaceutica que los contiene.
NO922182A NO301713B1 (no) 1991-06-03 1992-06-02 Krystallinske oksatiolan-derivater
CA002311988A CA2311988C (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
SK1257-93A SK281249B6 (sk) 1991-06-03 1992-06-02 (-)cis-4-amino-1-(2-hydroxymetyl-1,3-oxatiolán-5-yl)-(1h)- -pyrimidín-2-ón v kryštalickej forme, spôsob jeho prípravy a farmaceutický prostriedok s jeho obsahom
ES92109221T ES2171158T3 (es) 1991-06-03 1992-06-02 Derivados de oxatiolano cristalizados.
EP92109221A EP0517145B1 (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
ZA924007A ZA924007B (en) 1991-06-03 1992-06-02 Crystalline oxathiolane derivatives
CS932612A CZ284513B6 (cs) 1991-06-03 1992-06-02 (-)cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan 5-yl)-(1H)-pyrimidin-2-on v krystalické formě
JP4166809A JP2851480B2 (ja) 1991-06-03 1992-06-02 結晶オキサチオラン誘導体
IE178092A IE921780A1 (en) 1991-06-03 1992-07-01 Crystalline oxathiolane derivatives
IE20020782A IE20020782A1 (en) 1991-06-03 1992-07-01 Crystalline oxathiolane derivatives
IS4268A IS4268A (is) 1991-06-03 1992-12-04 Kristallaðar oxathiolane afleiður
OA60437A OA09913A (en) 1991-06-03 1993-11-15 Crystalline oxathiolane derivatives.
BG98254A BG60914B1 (bg) 1991-06-03 1993-11-30 Кристални оксатиоланови производни
HK98110312.3A HK1009599B (en) 1991-06-03 1998-08-31 Crystalline oxathiolane derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds

Publications (1)

Publication Number Publication Date
GB9111902D0 true GB9111902D0 (en) 1991-07-24

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919111902A Pending GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds

Country Status (30)

Country Link
US (1) US5905082A (enExample)
EP (2) EP1099700A1 (enExample)
JP (1) JP2851480B2 (enExample)
KR (1) KR100244008B1 (enExample)
AP (1) AP300A (enExample)
AT (1) ATE212630T1 (enExample)
AU (2) AU1881092A (enExample)
BG (1) BG60914B1 (enExample)
CA (2) CA2070230C (enExample)
CZ (1) CZ284513B6 (enExample)
DE (1) DE69232387T2 (enExample)
DK (1) DK0517145T3 (enExample)
ES (1) ES2171158T3 (enExample)
GB (1) GB9111902D0 (enExample)
GE (1) GEP19991834B (enExample)
IE (2) IE921780A1 (enExample)
IL (1) IL102073A (enExample)
IS (2) IS1867B (enExample)
MX (1) MX9202619A (enExample)
NO (1) NO301713B1 (enExample)
NZ (1) NZ242981A (enExample)
OA (1) OA09913A (enExample)
PT (1) PT517145E (enExample)
RU (1) RU2102393C1 (enExample)
SG (1) SG52455A1 (enExample)
SK (1) SK281249B6 (enExample)
TW (1) TW254939B (enExample)
UA (1) UA41265C2 (enExample)
WO (1) WO1992021676A1 (enExample)
ZA (1) ZA924007B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1997049411A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
PT1574512E (pt) * 2001-03-01 2008-03-05 Abbott Lab Formas polimórficas e outras formas cristalinas de cis-ftc
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003291457A1 (en) * 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
ES2318575T3 (es) * 2004-11-10 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Interferon beta desamidado.
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US8158607B2 (en) 2006-04-18 2012-04-17 Lupin Limited Crystalline form of lamivudine
AR068374A1 (es) * 2007-09-06 2009-11-11 Combino Pharm Sl Nuevas composiciones farmaceuticas del complejo lamivudina beta - ciclodextrina
US20100190982A1 (en) * 2007-09-17 2010-07-29 Janardhana Rao Vascuri Process for the preparation of lamivudine form i
BRPI0820222A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Forma i cristalina estável de lamivudina e processo de preparação
EP2227478A1 (en) * 2007-11-29 2010-09-15 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1, 3-oxathiolanes, especially lamivudine
WO2009069011A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
EP2318398A4 (en) * 2008-09-01 2011-12-07 Hetero Research Foundation PROCESS FOR PREPARING A POLYMORPHIC FORM OF LAMIVUDIN
EP2350065A1 (en) * 2008-11-12 2011-08-03 Lupin Ltd. A novel polymorph of emtricitabine and a process for preparing of the same
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
US8481554B2 (en) * 2009-05-27 2013-07-09 Hetero Research Foundation Solid oral dosage forms of lamivudine
WO2011007367A1 (en) 2009-07-15 2011-01-20 Lupin Limited An improved process for preparation of efavirenz
EP2488516B1 (en) 2009-10-14 2015-04-01 Mylan Laboratories Limited Process for the preparation of lamivudine and novel salts in the manufacture thereof
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
WO2011095987A1 (en) * 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
AU2011215878A1 (en) 2010-02-12 2012-08-09 Merck Sharp & Dohme Corp. Preparation of lamivudine Form I
CN104203275A (zh) 2010-06-09 2014-12-10 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2013021290A1 (en) 2011-08-05 2013-02-14 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
JPH04358486A (ja) * 1991-06-04 1992-12-11 Toshiba Corp 高能率符号化信号処理装置

Also Published As

Publication number Publication date
WO1992021676A1 (en) 1992-12-10
NO301713B1 (no) 1997-12-01
IS4268A (is) 1995-02-27
TW254939B (enExample) 1995-08-21
AU1736192A (en) 1993-03-11
IE921780A1 (en) 1992-12-16
IS3873A (is) 1992-12-04
DE69232387D1 (de) 2002-03-14
CA2070230C (en) 2004-08-03
DE69232387T2 (de) 2002-09-26
IS1867B (is) 2003-05-02
JPH06211848A (ja) 1994-08-02
NZ242981A (en) 1994-04-27
SK281249B6 (sk) 2001-01-18
RU2102393C1 (ru) 1998-01-20
AU656379B2 (en) 1995-02-02
DK0517145T3 (da) 2002-05-06
OA09913A (en) 1994-09-15
MX9202619A (es) 1992-12-01
EP0517145A1 (en) 1992-12-09
ES2171158T3 (es) 2002-09-01
AU1881092A (en) 1993-01-08
CZ284513B6 (cs) 1998-12-16
NO922182L (no) 1992-12-04
KR100244008B1 (ko) 2000-03-02
SG52455A1 (en) 1998-09-28
IE20020782A1 (en) 2003-04-02
CZ261293A3 (en) 1994-04-13
PT517145E (pt) 2002-07-31
SK125793A3 (en) 1994-11-09
GEP19991834B (en) 1999-11-05
UA41265C2 (uk) 2001-09-17
CA2311988A1 (en) 1992-12-04
BG98254A (bg) 1994-07-29
IL102073A0 (en) 1993-01-14
ZA924007B (en) 1993-04-28
IL102073A (en) 1996-05-14
US5905082A (en) 1999-05-18
EP0517145B1 (en) 2002-01-30
CA2070230A1 (en) 1992-12-04
EP1099700A1 (en) 2001-05-16
AP300A (en) 1994-01-20
KR930000511A (ko) 1993-01-15
NO922182D0 (no) 1992-06-02
HK1009599A1 (en) 1999-06-04
BG60914B1 (bg) 1996-06-28
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
CA2311988C (en) 2005-11-15
JP2851480B2 (ja) 1999-01-27

Similar Documents

Publication Publication Date Title
AP9200385A0 (en) Chemical compounds
GB9110636D0 (en) Chemical compounds
GB9103862D0 (en) Chemical compounds
GB9110625D0 (en) Chemical compounds
EP0585383A4 (en) Chemical compounds
GB9109497D0 (en) Chemical compounds
GB9110635D0 (en) Chemical compounds
GB9110623D0 (en) Chemical compounds
GB9110507D0 (en) Chemical compounds
GB9110095D0 (en) Chemical compounds
GB9100440D0 (en) Chemical compounds
GB9104889D0 (en) Chemical compounds
GB9110633D0 (en) Chemical compounds
GB9100421D0 (en) Chemical compounds
GB9100628D0 (en) Chemical compounds
GB9100427D0 (en) Chemical compounds
GB9100419D0 (en) Chemical compounds
GB9100439D0 (en) Chemical compounds
GB9100423D0 (en) Chemical compounds
GB9100433D0 (en) Chemical compounds
GB9100438D0 (en) Chemical compounds
GB9102690D0 (en) Chemical compounds
GB9124788D0 (en) Chemical compounds
GB9104888D0 (en) Chemical compounds
GB9100429D0 (en) Chemical compounds